Rilzabrutinib Patent Expiration
Rilzabrutinib was first introduced by Genzyme Corp
Rilzabrutinib Patents
Given below is the list of patents protecting Rilzabrutinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Wayrilz | US11708370 | Solid Forms Of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxyphenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile | Feb 20, 2041 | Genzyme Corp |
| Wayrilz | US12178818 | Methods For Treating Immune Thrombocytopenia By Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile | Oct 13, 2040 | Genzyme Corp |
| Wayrilz | US8940744 | Pyrazolopyrimidine Compounds As Kinase Inhibitors | Sep 06, 2033 | Genzyme Corp |
| Wayrilz | US9266895 | Substituted Pyrazolo[3,4-D]Pyrimidines As Kinase Inhibitors | Sep 06, 2033 | Genzyme Corp |
| Wayrilz | US9994576 | Substituted Pyrazolo[3,4-D]Pyrimidines As Kinase Inhibitors | Sep 06, 2033 | Genzyme Corp |
| Wayrilz | US9580427 | Kinase Inhibitors | Mar 01, 2033 | Genzyme Corp |
Rilzabrutinib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List